Roche Drug Proven Worthy To Extend The Life Of Patients Suffering From Breast Cancer

September 29, 2014 12:27 AM

7 0

Roche Drug Proven Worthy To Extend The Life Of Patients Suffering From Breast Cancer

Recently, Roche pharmaceutical manufacturer has given an account of the effective combination therapy against breast cancer. The company reported that the women suffering from breast cancer that tests positive for HER2 protein respond better to combination chemotherapy- Perjeta and Herceptin. Perjeta and Herceptin target the HER2 protein which is produced by a cancer-linked gene and has shown better consequences in breast cancer. Although Herceptin (trastuzumuab) is more commonly used however Roche reports that Perjeta (pertuzumab) injected to patients simultaneously with Herceptin has yielded better outcomes.

According to the company , the life of the victims administered this combination of drugs is expected to increase approx.15.7 months more in contrast to patients given single chemotherapeutic agent-Herceptin. The combined therapy offers longest survival for women with metastatic breast cancers. Over...

Read more

To category page

Loading...